Target intelligence / Profile preview

T cell receptor alpha joining 3 (TRAJ3)

Target: TRAJ3
Molecular classification: Other

Overview

T cell receptor alpha joining 3 (TRAJ3) is a gene segment within the T cell receptor alpha locus, classified as a "joining" (J) region segment. It contributes to the diversity of the T cell receptor (TCR) by recombining with variable (V) and constant (C) gene segments during TCR development. The resulting receptor, composed of an alpha and a beta chain, is essential for antigen recognition by alpha-beta T cells and plays an integral part in the adaptive immune system. However, TRAJ3 itself is not a receptor, enzyme, or protein target, but rather a short genomic element required for assembling functional TCR alpha chains and is not considered a drug or therapeutic target[2][3][5][6][8].

Other names: TRAJ3TJA3

Biological functions

Adaptive immune responseAntigen recognition

Beyond the preview

Go deeper on T cell receptor alpha joining 3 (TRAJ3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha joining 3 (TRAJ3).

Explore the full profile